Management of multiple myeloma in asia: Resource-stratified guidelines

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages

  Tan, Daryl ^a,b   Chng, Wee Joo ^c,d   Chou, Takaaki ^e   Nawarawong, Weerasak ^f   Hwang, Shang Yi ^g   Chim, Chor Sang ^h   Chen, Wenming ⁱ   Durie, Brian G M ^j   Lee, Jae Hoon ^k  

^a RAFFLES HOSPITAL   (Singapore)

^b SGP General Hospital   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NIIGATA CANCER CENTER HOSPITAL   (Japan)

^f Chiang Mai Medical School   (Thailand)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k Gachon University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; ELOTUZUMAB; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLERIXAFOR; POMALIDOMIDE; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

AGED; ASIA; ASIAN; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DEVELOPING COUNTRY; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; LOW DRUG DOSE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERIPHERAL NEUROPATHY; POSITRON; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; VENOUS THROMBOEMBOLISM;

ASIA; DELIVERY OF HEALTH CARE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MEDICAL ONCOLOGY; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886685262     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70404-2     Document Type: Review

References (82)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Kang SH, Kim TY, Kim HY, et al. Protective Role of CYP1A1 2A in the development of multiple myeloma. Acta Haematol 2008, 119:60-64.
3. Lee JH, Lee DS, Lee JJ, et al. Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. Int J Hematol 2010, 92:52-57.
4. Huang SY, Yao M, Tang JL, et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer 2007, 110:896-905.
5. Khan MM, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev 2006, 7:575-581. JACC Study group.
6. Park HK, Lee KR, Kim YJ, et al. Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. Am J Hematol 2011, 86:752-755.
7. Watanaboonyongcharoen P, Nakorn TN, Rojnuckarin P, et al. Prevalence of monoclonal gammopathy of undetermined significance in Thailand. Int J Hematol 2012, 95:176-181.
8. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
9. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006, 107:3492-3494.
10. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010, 89:201-206.
11. Wu SY, Yeh YM, Chen YP, et al. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Ann Hematol 2012, 91:1773-1778.
12. Lee JH, Kim K, Kim JS, et al. Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 8097.
13. Data and statistics: country classification World Bank, (accessed April 19, 2013). http://go.worldbank.org/K2CKM78CC0.
14. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 2008, 113:2221-2243.
15. Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011, 154:32-75.
16. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705.
17. Kyle RA, Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
18. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
19. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR Serum-free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001, 97:2900-2902.
20. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. International Myeloma Working Group.
21. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007, 25:1121-1128.
22. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009, 23:1545-1556.
23. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011, 118:5989-5995.
24. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
25. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
26. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
27. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
28. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006, 20:2034-2040.
29. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
30. Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013, 27:711-717.
31. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010, 95:1150-1157.
32. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012, 26:349-355.
33. Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28:827-838.
34. Meissner T, Seckinger A, Reme T, et al. Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 2011, 17:7240-7247.
35. Cavo M, Sonneveld P, Moreau P, et al. Impact of bortezomib incorporated into autotransplantation on outcomes of myeloma patients with high-risk cytogenetics: an integrated analysis of 1894 patients enrolled in four European phase 3 studies. 54th American Society of Hematology Annual Meeting; Atlanta, Georgia, USA; Dec 8-11, 2012; abstr 749.
36. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
37. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
38. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol 2009, 147:347-351.
39. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
40. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
41. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
42. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
43. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J The relationship between the serum-free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009, 114:38-39.
44. Giarin MM, Giaccone L, Sorasio R, et al. Serum-free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem 2009, 55:1510-1516.
45. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
46. Ladetto M, Drandi D, Cavallo F, et al. Long-term results of the GIMEMA VTD consolidation trial in autografted multiple myeloma patients (VEL-03-096): impact of minimal residual disease detection by real time quantitative PCR on late recurrences and overall survival. 53rd American Society of Hematology Annual Meeting; San Diego, CA, USA; Dec 10-13, 2011; abstr 827.
47. Dingli D, Pacheco JM, Nowakowski GS, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007, 25:4933-4937.
48. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011, 117:6063-6073.
49. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005, 106:3755-3759.
50. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
51. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
52. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
53. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012, 120:1589-1596.
54. Boccadoro M, Cavallo F, Nagler A, et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 8020.
55. Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
56. Rifkin R, Gregory SA, Mohrbacher A, Hussein M Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006, 106:848-858.
57. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007, 25:2434-2441.
58. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010, 28:4521-4530.
59. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
60. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow up. J Clin Oncol 2011, 29:3016-3022.
61. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367:825-831.
62. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011, 25:689-696.
63. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
64. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
65. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:5101-5109.
66. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012, 366:1759-1769.
67. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
68. Ludwig H, Hajek R, Tothova E, et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2008, 113:3435-3442.
69. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. 53rd American Society of Hematology Annual Meeting; San Diego, CA, USA; Dec 10-13, 2011; abstr 478.
70. Moreau P The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 2012, 49:33-46.
71. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120:2817-2825.
72. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011, 118:2970-2975.
73. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423.
74. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011, 29:986-993.
75. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25:2464-2472.
76. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992, 340:1049-1052.
77. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035-1043.
78. Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011, 12:743-752.
79. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26:4784-4790.
80. Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012, 23:421-426.
81. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
82. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010, 11:1086-1095.